HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: Comparison of automated dual ish to fish

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 6, 2013, Pages 561-566

  Grin, Andrea ^a   Brezden Masley, Christine ^a   Bauer, Sharon ^b   Streutker, Catherine J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Dual in situ hybridization; Fluorescence in situ hybridization; Gastric cancer; HER2; Heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADENOCARCINOMA; ARTICLE; AUTOMATIC SLIDE STAINER; CELL HETEROGENEITY; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DUAL IN SITU HYBRIDIZATION; ESOPHAGEAL ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LOWER ESOPHAGUS SPHINCTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADENOCARCINOMA; AUTOMATION, LABORATORY; CENTROMERE; CHROMOSOMES, HUMAN, PAIR 17; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892438806     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182849826     Document Type: Article

References (14)

1. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
2. Garcia-Garcia E, Gomez-Martin C, Angulo B, et al. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: A comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology. 2011;59:8-17.
3. Yan B, Yau EX, Choo SN, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64:880-883.
4. Langer R, Rauser S, Feith M, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol. 2011; 24:908-916.
5. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
6. Lee S, de Boer WB, Fermoyle S, et al. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 2011;59:832-840.
7. Yang J, Luo H, Li Y, et al. Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens. Cell Biochem Biophys. 2012;62:221-228.
8. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: A practical approach. Mod Pathol. 2012;25:637-650.
9. Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 2011;59:822-831.
10. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-394.
11. Carbone A, Botti G, Gloghini A, et al. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn. 2008;10:527-536.
12. Fox SB, Kumarasinghe MP, Armes JE, et al. Gastric HER2 Testing Study (GaTHER): An evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. Am J Surg Pathol. 2012;36:577-582.
13. Bartlett JM, Campbell FM, Ibrahim M, et al. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. Am J Clin Pathol. 2011;135:157-162.
14. Hofmann M, Stoss O, Gaiser T, et al. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: Assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol. 2008;61:89-94.